No longer trading

Acquired by Servier Pharmaceuticals LLC

The acquisition closed on April 23, 2026 (SEC 8-K 2.01). Its last closing price was on April 22, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from April 20, 2026. Source: SEC 8-K 2.01

DAWN

Day One Biopharmaceuticals, Inc. DAWN

NasdaqMid CapHealthcare

Final 13F Pro quality score

Final rank #2,384 of 2,819 · as of April 20, 2026

Why it scores 30Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$53.72M

Quarter to Dec 31

Net income

$-107.24B

Quarter to Dec 31

Free cash flow

$-14.15M

Quarter to Dec 31

Operating margin

-51.1%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$3.6K total
IFP Advisors, Inc
$3.6K-74.2%
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2025
EDGAR

Net Income

Q4 2025
EDGAR

Operating Margin

Q4 2025
EDGAR

ROIC

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DAWN

Earnings Per Share

13fpro.ai/company/DAWN

Loading ratio trend…

DAWN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Day One Biopharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Day One Biopharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$158.2M$-107.3B-80.8%
FY 2024$131.2M$-95.5B-165.7%
Source: DAWN filings on SEC EDGAR →

DAWN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Day One Biopharmaceuticals, Inc. (DAWN): stock profile, AI score and financials

Acquired by Servier Pharmaceuticals LLC: Day One Biopharmaceuticals, Inc. (DAWN) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on April 23, 2026 (SEC 8-K 2.01). Its last closing price was on April 22, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from April 20, 2026. Day One Biopharmaceuticals, Inc. (DAWN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks DAWN using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q4 2025), Day One Biopharmaceuticals, Inc. reports quarterly revenue of $53.7M, net income of $-107.2B, an operating margin of -51.1%. DAWN trades on the Nasdaq exchange and files with the SEC under CIK 1845337. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DAWN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Day One Biopharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1845337 →